Performance of Whole-Body PET/CT for the Detection of Distant Malignancies in Various Cancers: A Systematic Review and Meta-Analysis
Authors:
- 16 October 2012
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 53 (12) , 1847-1854
Abstract
At present, there is no ideal imaging modality for the diagnosis of distant metastases and second primary cancers in cancer patients. We aimed to assess the accuracy of whole-body PET/CT for the overall assessment of distant malignancies in patients with various cancers. Methods: Studies about whole-body PET/CT for the detection of distant malignancies in cancer patients were systematically searched in MEDLINE and EMBASE. We determined sensitivities and specificities across studies, calculated positive and negative likelihood ratios, and constructed summary receiver operating characteristic curves using hierarchical regression models for whole-body PET/CT. Results: Across 41 studies (4,305 patients), the sensitivity and specificity of whole-body PET/CT were 0.93 (95% confidence interval [CI], 0.88–0.96) and 0.96 (95% CI, 0.95–0.96), respectively. Subgroup analysis showed that the sensitivity and specificity of whole-body PET/CT for various cancers, respectively, were as follows: head and neck cancer, 0.90 (95% CI, 0.83–0.95) and 0.95 (95% CI, 0.94–0.96); lung cancer, 0.91 (95% CI, 0.76–0.97) and 0.96 (95% CI, 0.94–0.98); breast cancer, 0.97 (95% CI, 0.93–0.99) and 0.95 (95% CI, 0.90–0.97); and cancer of digestive system, 0.92 (95% CI, 0.68–0.98) and 0.97 (95% CI, 0.91–0.99). Conclusion: Whole-body PET/CT has excellent diagnostic performance for the overall assessment of distant malignancies in patients with various cancers, especially head and neck cancer, breast cancer, and lung cancer.Keywords
This publication has 40 references indexed in Scilit:
- Role of positron emission tomography in management of sinonasal neoplasms—a single institution's experienceAmerican Journal of Otolaryngology, 2012
- 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniquesBreast Cancer Research and Treatment, 2011
- FDG-PET/CT Compared with Conventional Imaging in the Detection of Distant Metastases of Primary Breast CancerThe Oncologist, 2011
- Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder CancerJournal of Clinical Oncology, 2010
- The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniquesEuropean Journal of Surgical Oncology, 2010
- A Prospective Diagnostic Accuracy Study of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography, Multidetector Row Computed Tomography, and Magnetic Resonance Imaging in Primary Diagnosis and Staging of Pancreatic CancerAnnals of Surgery, 2009
- Accuracy of MRI and 18F‐FDG PET/CT for Restaging After Preoperative Concurrent Chemoradiotherapy for Rectal CancerWorld Journal of Surgery, 2009
- Identification of distant metastases with PET‐CT in patients with suspected recurrent head and neck cancerThe Laryngoscope, 2009
- Positron Emission Tomography/Computed Tomography and Whole-Body Magnetic Resonance Imaging in Staging of Advanced Nonsmall Cell Lung Cancer???Initial ResultsInvestigative Radiology, 2008
- High-Resolution Whole-Body Magnetic Resonance Image Tumor Staging With the Use of Parallel Imaging Versus Dual-Modality Positron Emission Tomography–Computed TomographyInvestigative Radiology, 2005